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Abstract: Human Papilloma Virus (HPV) related verrucae pedis persist, seemingly 
evading host immune surveillance, yet sometimes disappear with inflammation. The 
absence, or reduction, of a cellular immune response may explain why verrucae treatments 
are not uniformly successful and treatment can be difficult even in immune-competent 
individuals. Little investigation has been undertaken into the potential benefit and efficacy 
of needling verrucae, a treatment modality causing HPV infected keratinocyte destruction 
in addition to inducing an assumed enhanced immune response. A review of clinical 
practice is presented, reporting the treatment method and results of data collected from a 
retrospective review of 45 patients. Thirty-one (69%) cases demonstrated complete 
resolution of verrucae following needling treatment. Three patients demonstrated reduction 
in size and pain whilst 11 showed no improvement. No adverse events were noted. 
Needling may have a place in the management of verrucae pedis in an adult population but 
a large scale study utilising objective measures and a control intervention would provide 
more detailed efficacy data along with a greater understanding of the effects of this 
treatment on long term immunity.  
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1. Introduction  
Verrucae (plantar warts) are a notorious source of frustration for both practitioners and patients 
alike, as no single treatment is completely effective in all patients. Despite a plethora of medical 
literature on this subject, high quality evidence for the efficacy of almost all treatments is  
non-existent [1,2]. A review by Lipke [3] also stated that although evidenced based reviews with 
guidelines have been published, they do not cover treatments that have yet to be subjected to blinded 
randomized, controlled clinical trials. Moreover, Lipke asserted that lack of robust evidence of a 
therapy, which has not been subjected to such rigorous scientific testing, does not mean that it is not 
worth knowing about nor worthy of use in practice, particularly when a specific treatment has been 
utilised and reported, albeit anecdotally, with a reasonably high clinical success rate. This article is a 
patient-centred, review of clinical practice of one such verrucae treatment, which was first described 
by Falknor [4] in 1969, the method of which he termed “needling”.  
Verrucae are benign tumours, caused by infection of epidermal keratinocytes by the double stranded 
DNA Human Papilloma Virus (HPV). There are currently more than 100 known types of HPV and 
these determine the anatomical distribution and morphology of the lesion [5]. The most common warts 
on the hands and feet are the subtypes 1, 2 and 4 [6].  
Infection of the keratinocyte at the basal layer of the epidermis is established through abrasions of 
the skin surface. Here, the virus remains latent in the cell from 1 to 8 months [7]. As the epidermal 
cells differentiate and migrate to the surface, the virus is triggered to undergo replication and 
maturation until it is shed in the exfoliation of the epidermis. The process of virus replication produces 
proliferation of prickle cells which alters the character of the epidermis, resulting in the visible warty 
appearance of the verrucae. 
In most viral infections, the viral proteins within a cell cause damage to the host cell and stimulate 
production of cytotoxic T cells, which then seek out and destroy the targeted infected cells. However, 
unlike many viruses, HPV prevents cell lysis as infection spreads through the shedding of infected 
epithelial cells from the surface of the skin. In other words, there is no (or indeed limited) release of 
viral proteins to the circulating dentritic cells, and therefore, no (or inadequate) antigen presentation to 
the immune system. Furthermore, HPV proteins also encode specific functions to inhibit immune 
responses by inducing specific anti-inflammatory mechanisms by activating T suppressor cells.  
Frazer [8] explains that “such inhibition would be expected to reduce specific antiviral defence 
mechanisms and also effective presentation of antigen to the host immune system”. 
The absence, or reduction, of a cellular response may explain why verrucae treatments are not 
uniformly successful and treatment can be difficult even in immune-competent individuals. Most 
treatments work by destroying affected tissues, by either a cytotoxic or physically ablative mode of 
action. However, tissue damage alone may not be enough to produce the relevant cytokines to destroy 
latent virus in adjacent cells [9], thus recurrence and further treatment is often required after apparent 
resolution [10]. Verrucae persist, evading host immune surveillance, but sometimes disappear with 
inflammation [11]. Sterling et al. [6] stated that despite the lack of antigens, HPV does sometimes 
induce an immune response and spontaneous regression is often seen, although warts are less likely to 
resolve in adults and in immuno-suppressed patients. Therefore, research into efficacy of verrucae 
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treatment for children must take into account the incidence of a higher rate of spontaneous  
regression [12].  
Frazer’s work concluded that induction of cell-mediated immunity to early proteins of HPV may 
prove useful as a therapeutic approach to HPV infection [8]. This is in agreement with Tyring [13] 
who also stated; “The ideal way to combat HPV infection would be to improve the immune response 
to the virus so it is specific and directed against early viral proteins.” One way of achieving this would 
be by better presentation of viral antigens to the immune system. Recent research on successful 
treatments has been aiming toward creating an enhanced systemic immune response to eradicate the 
virus [7]. This enhancement is required as although HPV does induce a localised immune response, it 
is not effective enough to trigger a systemic response because any expression of viral proteins are 
limited to superficial epithelial cells, thus there is a reduced presentation of these to the immune system.  
The work of Parton and Sommerville [14] asserted that resolution of a single plantar verruca in 
children aged 4–14 years could be successfully achieved by lightly debriding the lesion to produce 
capillary bleeding and then abraded with fine glass paper. Chapman [15] expanded upon this work in 
1998 and hypothesised that it should be possible to demonstrate a “whole body response” in patients 
with several verrucae in that the treatment of just one verruca will lead to the resolution of the 
untreated verrucae. Twenty-one patients participated in Chapman’s clinical trial with a wider age 
group range (aged 6–36 years) than that of Parton and Sommerville, who claimed an optimistic 94% of 
cases cleared within two weeks after one treatment. Chapman reported 43% success rate in participants 
aged 6–13 years. His conclusion concurred with Stirling’s observation; that treatment is more likely to 
be successful in patients under 14 years old.  
The ideal verrucae treatment should result in resolution of all or a great percentage of warts, be 
painless, need only one or a part of a lesion treated, create no scarring and offer HPV immunity  
for a lifetime. 
Falknor [4] first explained a direct needling procedure as a form of physical trauma without the use 
of chemicals (notwithstanding the use of local anaesthesia). The method he outlined comprised of 
anaesthetising the verruca, then thrusting in a needle “in dart fashion, so as to penetrate the full depth 
of the verruca and exiting through the base of the capsule into the fat”. He claimed only two 
recurrences of 126 lesions treated with this technique. Subsequent published research using this 
method has been sparse. Skilton and Mehar [16] published a case series of 14 patients with painful 
verrucae who were treated with the needling technique. They claimed resolution in 50% (7 out of the 14) 
had complete resolution at 8-week review. This paper retrospectively analyses 46 cases of verruca 
treated using Falknor’s needling method in a single private podiatry practice. The authors present a 
retrospective review of 46 cases (34 female, 12 male) treated within a private practice in Hampshire, 
UK using Falknor’s method.  
2. Experimental Section  
2.1. Methods 
Ethical approval was sought through the National Research Ethics Service for this study. Each 
patient presented with clinically diagnosed verruca pedis. Treatment was indicated where the patient 
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reported associated pain with the verrucae and subsequent interference with daily activities. However, 
a minority also requested clinical intervention as they perceived their quality of life was compromised 
due to cosmetic embarrassment. All treatment options, including no treatment, and the risks and 
benefits were explicitly explained to each patient. Those opting for needling treatment were enrolled 
into the study. Informed, signed consent was given by all patients prior to the needling procedure. 
Data from each patient was collected at baseline (prior to the procedure), one week post-operatively 
and at their final review to ascertain the following: 
• Previous treatment methods (at baseline only). 
• Location and duration of the lesion(s) (at baseline only). 
• Any discomfort throughout and at one and eight weeks post-operative (recorded as none, mild, 
moderate, severe). 
• Any post-operative infection or scarring following the procedure (at one and eight weeks). 
• Resolution or reduction in size of lesion (at eight weeks). 
2.2. Procedure 
Local anaesthetic (Mepivacaine® 3%) was administered by tibial nerve block, digital block or local 
infiltration according to the location of the lesion chosen for needling. Once the area of skin was 
anaesthetised, any overlying callus was debrided. If the patient presented with mosaic or multiple 
plantar warts the largest and thickest lesion was selected for treatment. All treatments were undertaken 
by a single operator (BL). 
The area surrounding the lesion was first cleansed with povidone-iodine before an empty 27 gauge 
needle was utilised to puncture through the lesion to the subcutaneous tissue (Figure 1). Each puncture 
produced pin point bleeding and this was continued until there was no more resistance, or reactive 
pressure, from the epidermis and the entire lesion was perforated enough to produce a beefy red wound 
(Figure 2). The total number of punctures varied according to the size of the lesion.  
Figure 1. Demonstrating the needling technique. 
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Figure 2. Wart. Immediately post-operatively after undergoing needling. 
 
Pressure was then applied to the wound with sterile gauze and then dressed with a non-adherent 
sterile dressing (Melolin®) and fixing tape (Mefix®). A semi compressed felt aperture pad was also 
applied on weight bearing sites to deflect pressure and reduce post-operative bruising. Each patient 
was issued with post-operative care sheets and advised to lightly shower and wash the area after 
keeping the dressing dry for 24 h. Each patient was advised to avoid taking NSAIDs or other  
anti-inflammatory medication for 48 h to increase the likelihood of a successful controlled 
inflammatory response. Wound inspection and debridement of any uncomfortable eschar was 
performed one week later. The final inspection for verrucae resolution was carried out 8 weeks later. 
Complete resolution was deemed accomplished on return of normal dermatoglyphics to the treated 
lesion, i.e., uninterrupted skin striae and no pain on lateral compression of the area. Figure 3a–c 
demonstrate a lesion before, immediately after and six weeks following treatment. 
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Figure 3. (a) Lateral plantar lesion before treatment; (b) Same lateral plantar lesion during 




3. Results and Discussion  
A total of 46 patients (13 male, 33 female) underwent a standardised needling procedure. The mean 
age of the cohort was 41.8 years ± SD 12.65 (range 17–66 years). The average patient reported 
duration of the warts was 5.7 years ± SD 4.15 (range 1–20 years). The locations of all the treated 
lesions are given in Table 1. A total of 45 patients were available for review at eight weeks  
post-operatively with one patient lost to follow up. 
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Table 1. Location of primary (treated) lesions. 
Location Numbers 
Digits (plantar or apical aspect) 16 
Plantar Metatarsal Area 20 
Plantar Heel 7 
Base (Proximal end) of Metatarsal Area 3 
Of 45 patients, 69% (21 female and 10 male) demonstrated a complete resolution of verrucae  
(10 patients with single lesions, 8 with mosaic and 13 with multiple types). There was no significant 
difference in the cure rates between males and females (p = 0.463). Table 2 profiles previous 
treatments of the resolved and unresolved lesions. Of the 45 patients, 7 (2 single lesions, 2 mosaic 
lesions and 3 multiple lesions) opted for a second needling treatment as the initial treatment did not 
fully rid all lesions. 
Table 2. Previous treatment profile of resolved (R) and unresolved (U) lesions (n = 45). 
 
Salicylic Acid Cryotherapy 









U R U R U R U R U R  
Number 7 12 1 1 3 7 0 2 3 9 45 
Percentage % 16 27 2.2 2.2 6.7 15 0 4.4 6.7 20 100 
Lesions from 14 patients (31%) failed to resolve. There was no difference in the mean duration of 
resolved versus unresolved lesions (mean duration unresolved 7.67 years ± SD 13.26 versus mean 
resolved 6.68 years ± SD 4.41 (p = 0.7571). Three of the patients with unresolved lesions (7%) 
reported significant reduction of verrucae size and subsequent pain, signifying a clinical improvement. 
All treated patients reported their pain level after needling as either “none” (n = 29 [64%]) or “mild”  
(n = 16 [36%]) describing mild symptoms such as “bruising” or “slight discomfort”. No post-operative 
infection or scarring was evident on examination or reported by patients post-operatively. 
Discussion 
This paper represents the largest case series published to date using Falknor’s method since his 
original paper was published in 1969. The selection of patients from an adult population with a broad 
age range (17–66 years) has reduced the possibility of spontaneous regression often observed in child 
population based studies of this kind. The resolution rate following a maximum of two treatments 
(69%) indicates a good response when compared to other modalities. Using a similar approach of 
exposing wart virus to the immune system, Nischal et al. [17] auto-implanted debrided wart tissue 
from sufferers’ feet and implanted into the sub-cutis of the patients forearm or thigh. Analysis of the  
27 subjects demonstrated a similar 74% clearance of lesions within three months. 
The observed positive clinical outcomes, in this current review, suggest that the hypothesis; 
provocation of a cell-mediated response as the cause of verrucae regression, is a viable premise. 
Needling just one lesion often produced a “cascade” effect, whereby the remaining untreated lesions 
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also resolved in a number of patients. Thus, it can be suggested that introducing already HPV infected 
keratinocytes into the subcutaneous layer appears to facilitate a desired immune response in  
some patients. 
Currently the practice of needling verrucae is not extensively practiced. This may be due to many 
factors, including lack of published research, preference to utilise traditional and established 
treatments, (such as salicylic acid and cryotherapy) or simply because many practitioners require 
update in anaesthesic skills for ankle block infiltration.  
Although the short review period of eight weeks post-operatively, potentially does not rule out 
completely the possibility of reinfection or recurrence, longer term follow up is required. The authors 
acknowledge that this is small case series and cannot imply effectiveness and any placebo action 
inherent cannot be fully determined. However, a larger scale investigation, with objective measures 
using a control intervention, over a longer period of time would provide a more detailed picture of 
efficacy and long term immunity of the needling technique. 
4. Conclusions  
Currently, there is no consistently effective treatment for plantar warts. This case series has 
reviewed the potential for the use of a direct needling technique in the management of plantar warts in 
an adult population. Following treatment of 45 patients, complete resolution of warts after eight weeks 
was observed in 31 (69%) cases. This represents a relatively small case series, within a restricted 
clinical setting. However, a larger scale investigation, with objective measures using a control 
intervention would provide a more detailed picture of efficacy and long term immunity of this 
promising technique. 
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